Department of Nephrology, Transplant Center, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
Transplantation. 2012 Mar 27;93(6):589-96. doi: 10.1097/TP.0b013e31824491aa.
Induction therapy is associated with excellent short-term kidney graft outcome. The aim of this study was to evaluate differences in the intragraft transcriptome after successful induction therapy using two rabbit antithymocyte globulins.
The expression of 376 target genes involved in tolerance, inflammation, T- and B-cell immune response, and apoptosis was evaluated using the quantitative real-time reverse-transcriptase polymerase chain reaction (2(-ΔΔCt)) method in kidney graft biopsies with normal histological findings and stable renal function, 3 months posttransplantation after induction therapy with Thymoglobulin, ATG-Fresenius S (ATG-F), and a control group without induction therapy.
The transcriptional pattern induced by Thymoglobulin differed from ATG-F in 18 differentially expressed genes. Down-regulation of genes involved in the nuclear factor-κB pathway (TLR4, MYD88, and CD209), costimulation (CD80 and CTLA4), apoptosis (NLRP1), chemoattraction (CCR10), and dendritic cell function (CLEC4C) was observed in the biopsies from patients treated with Thymoglobulin. A hierarchical clustering analysis clearly separated the Thymoglobulin group from the ATG-F group, while the control group had a similar profile as the Thymoglobulin group.
Despite normal morphology in graft biopsy taken 3 months posttransplantation, the intrarenal transcriptome differed in patients treated with induction therapy using different rATGs. In the Thymoglobulin high-risk group, the transcriptome profile was identical to the low-risk group. Therefore, the down-regulation of the nuclear factor-κB pathway after Thymoglobulin induction in vivo is likely to explain the clinical success of this biologic.
诱导治疗与出色的短期肾移植物预后相关。本研究旨在评估两种兔抗胸腺细胞球蛋白成功诱导治疗后移植物内转录组的差异。
使用定量实时逆转录聚合酶链反应(2(-ΔΔCt))方法,在移植后 3 个月、组织学正常且肾功能稳定的肾移植物活检中,评估与耐受、炎症、T 和 B 细胞免疫反应和细胞凋亡相关的 376 个靶基因的表达,这些活检接受了 Thymoglobulin、ATG-Fresenius S(ATG-F)的诱导治疗和未接受诱导治疗的对照组。
Thymoglobulin 诱导的转录模式在 18 个差异表达基因中与 ATG-F 不同。在接受 Thymoglobulin 治疗的患者的活检中,观察到核因子-κB 途径(TLR4、MYD88 和 CD209)、共刺激(CD80 和 CTLA4)、凋亡(NLRP1)、趋化作用(CCR10)和树突状细胞功能(CLEC4C)相关基因下调。层次聚类分析清楚地将 Thymoglobulin 组与 ATG-F 组分开,而对照组与 Thymoglobulin 组具有相似的特征。
尽管移植后 3 个月的肾活检形态正常,但使用不同 rATG 进行诱导治疗的患者的肾内转录组存在差异。在 Thymoglobulin 高风险组中,转录组谱与低风险组相同。因此,体内 Thymoglobulin 诱导后 NF-κB 途径的下调可能解释了这种生物制剂的临床成功。